Live Analyst Rating Changes 1348 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jonathan Chang
LP
Jonathan Chang
Leerink Partners
Wall Street Analyst
★★★☆☆
#772
on 13Foresight · ranked by our own returns
69%
Success Rate
+13.5%
Average Return
11 of 16 calls profitable · +0.9% vs benchmark
📈 Across the calls we could measure, roughly 69% of Jonathan Chang's ratings turned a profit when each position was held for 1 year — averaging +13.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

41 Buy 8 Hold 0 Sell
Jonathan's Stock Coverage 19 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
REPL
Replimune Group
 Jun 02, 2026 HOLD Hold
+74.9% avg upside
13 analysts
 — +14.9%
MOLN
Molecular Partners
 Jun 02, 2026 BUY Strong Buy
+156.4% avg upside
7 analysts
 — ·
RVMD
Revolution Medicines
 Apr 13, 2026 BUY Strong Buy
-10.2% avg upside
32 analysts
$147.00
8.24% Downside
 +15.8%
NBTX
Nanobiotix
 Apr 01, 2026 BUY Strong Buy
-7.0% avg upside
5 analysts
$37.00
5.16% Upside
 +4.1%
IMTX
Immatics
 Mar 06, 2026 BUY Strong Buy
+90.4% avg upside
15 analysts
$17.00
75.25% Upside
 +10.2%
AKTS
Aktis Oncology, Inc.
 Feb 03, 2026 BUY Strong Buy
+32.6% avg upside
8 analysts
$31.00
29.15% Upside
 ·
KURA
Kura Oncology
 Jan 13, 2026 BUY Strong Buy
+170.6% avg upside
26 analysts
$20.00
107.11% Upside
 +3.9%
NVCR
NovoCure
 Jan 13, 2026 BUY Strong Buy
+212.7% avg upside
11 analysts
$24.00
65.39% Upside
 +28.8%
ZLAB
Zai Lab
 Oct 21, 2025 BUY Strong Buy
+226.5% avg upside
13 analysts
$74.00
300.28% Upside
 -41.4%
GMAB
Genmab
 Oct 13, 2025 BUY Buy
+38.1% avg upside
26 analysts
$39.00
54.54% Upside
 -18.8%
KPTI
Karyopharm Therapeutics
 Oct 10, 2025 HOLD Strong Buy
+139.5% avg upside
18 analysts
$6.00
33.45% Downside
 +39.5%
MGNX
MacroGenics
 Aug 18, 2025 BUY Buy
+341.3% avg upside
25 analysts
$5.00
23.83% Upside
 +173.7%
ADAPY
Adaptimmune Therapeutics
 Aug 13, 2025 HOLD Buy
+5717.9% avg upside
10 analysts
$0.09
157.13% Upside
 ·
BCYC
Bicycle Therapeutics
 Aug 11, 2025 BUY Strong Buy
+502.2% avg upside
20 analysts
$24.00
501.55% Upside
 -41.5%
IMCR
Immunocore Holdings
 Aug 11, 2025 BUY Strong Buy
+125.2% avg upside
22 analysts
$60.00
112.13% Upside
 -12.0%
XNCR
Xencor
 Aug 07, 2025 BUY Strong Buy
+157.0% avg upside
27 analysts
$27.00
111.41% Upside
 +54.0%
ARGX
Argenx Se
 Jun 30, 2023 BUY Strong Buy
-16.4% avg upside
46 analysts
 — +10.3%
MP
MP Materials
 Jan 11, 2023 BUY Strong Buy
+10.9% avg upside
21 analysts
 — -39.4%
LINK
Interlink Electronics
 Jun 01, 2022 BUY Strong Buy
+126.0% avg upside
16 analysts
 — +14.5%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jonathan Chang — Frequently Asked Questions
How accurate are Jonathan Chang's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Jonathan's ratings were profitable over a one-year hold, with an average return of +13.4% per rating, or -0.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jonathan ranked on 13Foresight?
Jonathan Chang is currently ranked #772 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jonathan cover?
Jonathan most recently has ratings on REPL, MOLN, RVMD, NBTX, IMTX, AKTS, KURA, NVCR, ZLAB, GMAB, KPTI, MGNX and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.